MedTrace Logo

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

NCT00522808 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-09-29

No results posted yet for this study

Summary

The purposes of this study are:

* to determine the safety and tolerability of multiple doses of A-831 at various doses
* to determine how multiple doses of A-831 are distributed through the bloodstream
* to determine if A-831 reduces the amount of Hepatitis C virus in the blood

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

A-831

Sponsors & Collaborators

  • DDS, Dundee

    collaborator UNKNOWN

  • David Mutimer, Birmingham

    collaborator UNKNOWN

  • Ed Gane, ACS New Zealand

    collaborator UNKNOWN

  • Arrow Therapeutics

    lead INDUSTRY

Principal Investigators

  • Brian Sanderson · DDS

  • David Mutimer · WTCRF Birmingham

  • Edward Gane · ACS New Zealand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-03-31
Completion
2008-05-31

Countries

  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00522808 on ClinicalTrials.gov